ClinConnect ClinConnect Logo
Search / Trial NCT06345976

Functional Impairment in Albinism

Launched by FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD · Mar 28, 2024

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial, titled "Functional Impairment in Albinism," is looking into how albinism affects people's daily lives, especially their vision. Albinism is a genetic condition that leads to little or no color (pigmentation) in the skin, hair, and eyes, which can cause problems like poor eyesight and light sensitivity. The study aims to understand what difficulties patients with albinism face and to gather their thoughts on new treatments that could help reduce issues like glare from bright lights.

To join the trial, participants need to be adults (18 years or older) who have been diagnosed with albinism. They should be willing to take part in the study and be able to complete a questionnaire about their experiences. This trial is currently recruiting participants and is open to anyone who meets the eligibility criteria. Those involved can expect to share their insights and experiences, which could help shape future treatments for people with albinism.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All patients with albinism
  • Patients \> 18 years of age
  • Non-opposition to study participation
  • Exclusion Criteria:
  • No diagnosis according to Kruijt et al. criteria Impossibility (visual, technological) of completing questionnaire

About Fondation Ophtalmologique Adolphe De Rothschild

The Fondation Ophtalmologique Adolphe de Rothschild is a leading French institution dedicated to advancing ophthalmic research and patient care. Renowned for its commitment to innovation in eye health, the foundation conducts cutting-edge clinical trials aimed at improving treatments for various ocular conditions. With a multidisciplinary team of experts, the foundation collaborates with academic and industry partners to enhance understanding of eye diseases and develop novel therapeutic solutions, ultimately striving to improve patient outcomes and quality of life in ophthalmology.

Locations

Paris, , France

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported